Johnson & Johnson (JNJ)[Tv]

Key Developments

• FDA Priority Review of IMAAVY (nipocalimab-aahu): The FDA’s prioritization of the sBLA for IMAAVY, a first-in-class FcRn inhibitor for warm autoimmune hemolytic anemia, represents a pivotal regulatory milestone with transformative potential—backed by Phase 2/3 ENERGY trial data showing a threefold increase in durable hemoglobin response and reduced steroid dependence, positioning it as a potential blockbuster in a high-unmet-need rare disease space.

• EMA CHMP Recommendation for Tecvayli in Multiple Myeloma: The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended approval for Tecvayli (teclistamab) in combination with subcutaneous Darzalex for relapsed or refractory multiple myeloma—supported by Phase III data demonstrating an 83.4% reduction in disease progression or death and 83.3% three-year overall survival, confirming its potential as a new second-line gold standard.

• $1 Billion Vision Business Expansion in Jacksonville: Johnson & Johnson announced a $1 billion expansion of its Vision business in Jacksonville, Florida, signaling a strategic shift toward vertically integrated, onshored manufacturing of ACUVUE contact lenses—aimed at strengthening U.S. supply chain resilience, securing long-term margin growth, and reinforcing a bold commitment to domestic MedTech leadership.

• $1 Billion All-Cash Acquisition of Firefly Bio, Inc. (Expected 2026): JNJ’s planned $1 billion acquisition of Firefly Bio, a leader in degrader-antibody conjugate technology, marks its most consequential strategic move of the year, securing access to a breakthrough platform targeting KRAS-driven solid tumors—long considered “undruggable”—and reinforcing a generational leap in oncology innovation.